Moss-Agal
Fabry Disease
Greenovation Biotech GmbHPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
23 Active assets in the Fabry Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Recombinant Alpha-Galactosidase A Shire | Phase 4 | A |
Agalsidase Beta Sanofi | Phase 4 | A |
Pegunigalsidase Alfa Chiesi Italia | Phase 3 | A |
Migalastat Amicus Therapeutics | Phase 3 | BBB |
Loratadine Sanofi | Phase 4 | BB |
View all 37 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →